Filing Flows › Intellia Therapeutics (NTLA) › Q1 2026
Intellia Therapeutics (NTLA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 11, 2026
Intellia Therapeutics (NTLA) reported revenue of $15.0M for the first quarter 2026 (Q1 2026), -9% from a year earlier and -35% from the quarter before. Operating margin was -668.1%, net loss $96.2M (639.5% of revenue).
Intellia Therapeutics, Q1 2026: revenue $15.0M (-10% year over year), operating margin -668.1%, net loss $96.2M, operating cash flow −$117M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.0M | -35% | -9% |
| Operating profit | −$101M | — | — |
| Net earnings | −$96.2M | — | — |
| Operating cash flow | −$117M | — | — |
What changed
Revenue was $15.0M in Q1 2026, down 9% year over year and down 35% from the previous quarter.
Operating costs exceeded revenue by $100.5M, an operating margin of -668.1%. Total costs fell 16% while revenue fell 9%. The fastest-growing cost line was General & admin (+20%). The quarter ended with a net loss of $96.2M, wider than the previous quarter's $95.8M loss.
Operating cash flow was −$117.3M. Non-cash charges added back $2.2M of depreciation and amortization and $13.5M of share-based compensation. Working capital and other items used $36.8M. Capital expenditures of $79K exceeded it, leaving free cash flow of −$117.4M.
Questions
What was Intellia Therapeutics' revenue in the first quarter 2026?
Intellia Therapeutics (NTLA) reported revenue of $15.0M for the first quarter 2026 (Q1 2026), -9% from a year earlier and -35% from the quarter before.
Was Intellia Therapeutics profitable in the first quarter 2026?
Operating loss was $101M (-668.1% of revenue) and net loss $96.2M.